The tirzepatide formulation: what's inside Mounjaro and how it acts

Step 1 — what tirzepatide actually is as a molecule

Tirzepatide is a 39-amino-acid synthetic peptide. Its structure was deliberately engineered to bind two gut-hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIP-R) and the glucagon-like peptide-1 receptor (GLP-1R). This dual-agonist design is what sets the Mounjaro formulation apart from every other licensed weight-loss injection currently available in the UK, which act on GLP-1 alone.

The molecule is conjugated to a fatty-acid chain. That chain lets it bind loosely to albumin in the bloodstream, extending its half-life to roughly five days and making once-weekly dosing pharmacologically viable. Without that modification, a peptide this size would clear the body within hours. The chemical structure behind tirzepatide follows a design logic used across this class of injectable medicines, though the dual-receptor activity is unique to tirzepatide among UK-licensed weight-management treatments.

Understanding why the tirzepatide formula is built around a peptide rather than a small-molecule tablet also explains a practical reality: peptides are digested if swallowed, so injection is the delivery method. The KwikPen format puts the needle insertion and dose mechanism behind an automatic system, you do not handle a needle directly.

Step 2, how the drug reaches its receptors after injection

Once injected under the skin, tirzepatide diffuses into the subcutaneous tissue and is absorbed gradually into the circulation via the lymphatic system and local capillaries. Peak plasma concentration arrives roughly 24–48 hours after injection, which is why the once-weekly schedule produces a relatively stable blood level rather than a sharp spike-and-trough pattern.

From the bloodstream, tirzepatide binds GIP and GLP-1 receptors in multiple tissues. In the gut, it slows gastric emptying, meaning food moves from the stomach into the small intestine more slowly. That delay extends the sensation of fullness after eating. In the brain's appetite-regulating centres, GLP-1 receptor activation reduces hunger signalling. The GIP component adds a complementary signal that appears to amplify the overall appetite-suppressing effect, though the precise interaction between the two pathways is still being studied by researchers.

The NHS medicine page on tirzepatide provides a clear patient-level summary of how the drug works and what to expect during treatment. It is a reliable first reference if you want to read beyond the marketing.

Step 3, the dosing schedule and what it means for the formulation

Treatment begins at 2.5 mg. That starting strength is not chosen because 2.5 mg is therapeutically active at the weight-management level, it exists to give the body time to adjust to gastric slowing before moving to higher doses. The prescriber then titrates upward, typically in 4-week steps, through 5, 7.5, 10, 12.5, and up to 15 mg, depending on how a patient tolerates each level and the clinical picture at each review.

Each KwikPen holds four doses at a given strength. This means one pen per month at a fixed dose, which keeps the logistics straightforward. Injection sites should be rotated across the abdomen, thigh, and upper arm to avoid local tissue reactions building up in one area. Refrigerated storage at 2–8°C preserves the formulation's stability; the Mounjaro SmPC on the electronic medicines compendium (eMC) gives the verified window for how long a pen may be kept at room temperature once removed from the fridge.

Dose increases are a clinical decision, not a patient-led one. At Mounjaro through nume, every repeat order is reviewed by one of our prescribers before any change is made, evidence of current use and response is part of that assessment. The prescribing follows NICE technology appraisal TA1026, which recommends tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related health condition, with thresholds adjusted for certain ethnic backgrounds under the tirzepatide formulary guidance applied across UK services.

Side effects linked to the formulation's mechanism

Because tirzepatide slows gastric emptying and acts on gut receptors, the most common side effects follow directly from that mechanism: nausea, vomiting, diarrhoea, constipation, indigestion, and reflux. These tend to be most noticeable when treatment starts or immediately after a dose increase, and for most people they settle within a couple of weeks as the body adapts.

Two side effects are worth flagging specifically. Injection-site reactions (redness, itching, mild swelling) can occur where the needle is placed, which is why site rotation matters. More seriously, acute pancreatitis is a known but infrequent risk with GLP-1 class medicines, and understanding the tirzepatide molecular formula helps explain why its gut-receptor activity carries this class-level consideration. Severe, persistent stomach pain that reaches through to the back, with or without vomiting, needs same-day medical attention rather than a wait-and-see approach.

If you want a fuller picture of what to watch for, the weight-loss treatment overview at nume covers the safety considerations alongside the clinical evidence. Questions about whether a specific health history changes your risk profile are exactly the kind of thing a prescriber should review before any treatment starts. You can find out more about how our clinical team approaches that or explore common questions about treatment before you take the next step.

Cost is a fair consideration at this point, too, the context around Mounjaro pricing in the UK is worth reading if you are comparing options, because not all headline prices reflect the same level of clinical oversight.

When you are ready to talk to a clinician, speak to our prescribers through the free consultation, your answers are read the same day by a real person, not processed by software.